NATO
APTSIAURI
PROFESORA TITULAR DE UNIVERSIDAD
Publications (62) NATO APTSIAURI publications
2022
-
Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer
Pharmaceutics, Vol. 14, Núm. 3
-
The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and Hopes
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 23, pp. 5021-5029
2021
-
CRC: A Darwinian model of cellular immunoselection
Foundations of Colorectal Cancer (Elsevier), pp. 529-541
-
Copy neutral loh affecting the entire chromosome 6 is a frequent mechanism of hla class i alterations in cancer
Cancers, Vol. 13, Núm. 20
-
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy
Cellular and Molecular Immunology, Vol. 18, Núm. 3, pp. 556-565
-
Tumor escape phenotype in bladder cancer is associated with loss of HLA class I expression, T-cell exclusion and stromal changes
International Journal of Molecular Sciences, Vol. 22, Núm. 14
2019
-
A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer
Annals of Surgical Oncology, Vol. 26, Núm. 8, pp. 2631-2639
-
Cancer immune escape: MHC expression in primary tumours versus metastases
Immunology, Vol. 158, Núm. 4, pp. 255-266
2018
-
HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15
Immunogenetics, Vol. 70, Núm. 10, pp. 647-659
-
HLA class I loss and PD-L1 expression in lung cancer: Impact on T-cell infiltration and immune escape
Oncotarget, Vol. 9, Núm. 3, pp. 4120-4133
-
The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses
Current Opinion in Immunology, Vol. 51, pp. 123-132
2017
-
Rejection versus escape: the tumor MHC dilemma
Cancer Immunology, Immunotherapy, Vol. 66, Núm. 2, pp. 259-271
-
The escape of cancer from T cell-mediated immune surveillance: HLA class I loss and tumor tissue architecture
Vaccines, Vol. 5, Núm. 1
2016
-
Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance
Cancer Immunology, Immunotherapy, Vol. 65, Núm. 1, pp. 47-59
-
Generation of MHC class i diversity in primary tumors and selection of the malignant phenotype
International Journal of Cancer, Vol. 138, Núm. 2, pp. 271-280
-
Redefining cancer immunotherapy—optimization, personalization, and new predictive biomarkers: 4th Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, April 27–30, 2015, Ljubljana, Slovenia
Cancer Immunology, Immunotherapy, Vol. 65, Núm. 7, pp. 875-883
-
The urgent need to recover MHC class I in cancers for effective immunotherapy
Current Opinion in Immunology, Vol. 39, pp. 44-51
2014
-
Adenovirus expressing β2-microglobulin recovers HLA class i expression and antitumor immunity by increasing T-cell recognition
Cancer Gene Therapy, Vol. 21, Núm. 8, pp. 317-332
-
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
International Journal of Cancer, Vol. 134, Núm. 1, pp. 102-113
2013
-
MHC class I antigens in malignant cells: Immune escape and response to immunotherapy
Springer New York, pp. 1-51